Zhou, Y., Lin, Z., Zhang, X., Chen, C., Zhao, H., Hong, S., & Zhang, L. (2019). First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: Pembrolizumab or pembrolizumab plus chemotherapy. J Immunother Cancer.
Citação norma ChicagoZhou, Yixin, Zuan Lin, Xuanye Zhang, Chen Chen, Hongyun Zhao, Shaodong Hong, and Li Zhang. "First-line Treatment for Patients With Advanced Non-small Cell Lung Carcinoma and High PD-L1 Expression: Pembrolizumab or Pembrolizumab Plus Chemotherapy." J Immunother Cancer 2019.
ציטוט MLAZhou, Yixin, et al. "First-line Treatment for Patients With Advanced Non-small Cell Lung Carcinoma and High PD-L1 Expression: Pembrolizumab or Pembrolizumab Plus Chemotherapy." J Immunother Cancer 2019.